Log in to your Inderes Free account to see all free content on this page.
Biovica International
0.32 SEK
+0.31 %
Less than 1K followers
BIOVIC B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
+0.31 %
-6.43 %
-20.40 %
-13.51 %
-42.86 %
-50.31 %
-94.95 %
-99.08 %
-96.88 %
Biovica International is a pharmaceutical company that focuses its research on cancer treatment. The company develops blood-based biomarker tests to monitor and evaluate cancer treatments. The tests analyze the risk of developing the enzyme thymidine kinase, an enzyme that is linked to tumor growth. The main focus is on the treatment of breast cancer. Biovica International was founded in 2008 and is headquartered in Uppsala.
Read moreMarket cap
93.41M SEK
Turnover
273.16K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
17.6.
2026
Annual report '26
10.9.
2026
Interim report Q1'27
16.9.
2026
General meeting '26
All
Webcasts
Press releases
3rd party
ShowingAll content types
Theis Kipling new CEO for Biovica
Redeye: Biovica (Q3 Review): Execution key as revenue drivers emerge
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
